Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD5+ Relapsed/Refractory Hematopoietic Malignancies”

2 trials

Showing 2 of 2 results

Very early researchUnknownNCT04767308
What this trial is testing

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Who this might be right for
CD5+ Relapsed/Refractory Hematopoietic MalignanciesChronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)+3 more
Huazhong University of Science and Technology 18
Not applicableLooking for participantsNCT07234110
What this trial is testing

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

Who this might be right for
Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China 18

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation